Grab a quick cup of tea or coffee from the comfort of your own home office and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network
and form lasting connections through this exclusive virtual speed networking!
9:10 am
Panel: What Progress Has There Been in Achieving Antigen Specific Therapeutics
Simi Ahmed
Director of Research & Lead of the Immune Therapies Program, JDRF
Jose Carballido
Executive Director (Translational Medicine/ Preclinical Safety), Novartis
David Wraith
Founder & Chief Scientific Officer – Apitope; Director, Institute of Immunology & Immunotherapy, University of Birmingham
10:00 am
Success Story: Gliadin-Encapsulating Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease – Results of A Phase 1/ 2 Placebo-Controlled Clinical Trial
Ciaran P. Kelly
Professor of Medicine/Chief/Director/Medical Director, Harvard Medical School/Herman L. Blumgart Internal Medicine Firm/Gastroenterology Fellowship Training/Celiac Center
10:30 am
Challenges in Defining & Measuring Immunological Tolerance in the Long Term
Andreas Lutterotti
Head of Experimental Therapies Research, University Hospital Zurich
11:00 am
Digital Speed Networking
Immune Tolerance using Gene Therapy Approaches
11:40 am
Challenges and Opportunities for Immune Tolerance Induction in AAV Gene Therapy
Dr Bruce Mazer
Associate Scientific Director, Strategy , Canadian Covid-19 Immunity Task Force
2:10 pm
Induction of cytolytic phenotype in human and mouse CD4+ T-cells by MOG-derived Imotopes™ and validation of the immunosuppressive capacity in mouse models of Multiple Sclerosis
Saso Cermerski
VP & Head of Discovery & Translational Immunology, Cue Biopharma
5:10 pm
Shielded Living Therapeutics (SLTx): A novel allogeneic cell therapy platform for induction of antigen-specific immune tolerance & restoration of immune homeostasis.
Hozefa Bandukwala
Vice President, Platform Innovation and Biology, Sigilon